On the stock market since 2007, it operates in the world of health and science. It has 1,202 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 7% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $6.7B would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 52% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 40% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 8% a year on average.
There is $6.7B in the vault; even if every debt were paid off, $6.7B would remain.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, CO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CO is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.